Pharmacogenomics--drug disposition, drug targets, and side effects.
about
Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variantsCharting the molecular network of the drug target Bcr-AblSubstrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductaseGenome-environment interactions that modulate aging: powerful targets for drug discoveryNon-cancer health effects of pesticides: systematic review and implications for family doctorsGenetics of migraine and pharmacogenomics: some considerationsThe reality of pharmacogenomics: optimizing therapeutic decision makingThe effect of ABCB1 polymorphisms on the outcome of breast cancer treatmentTaking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease ResearchCurrent stage in inflammatory bowel disease: What is next?Systems pharmacology: network analysis to identify multiscale mechanisms of drug actionA conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomicsSystems pharmacology of complex diseasesCan knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Individualized medicine enabled by genomics in Saudi ArabiaSniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapyPharmacotherapy of amphetamine-type stimulant dependence: an updateSystemic therapies for pancreatic cancer--the role of pharmacogeneticsEvaluation of the effect of genetic variation on the relationship between statins, cardiovascular disease and cancerCausality assessment in hepatotoxicity by drugs and dietary supplementsA national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicinePharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision MedicinePersonalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicineThe potential utility of pharmacogenetic testing in psychiatryDrug methylation in cancer therapy: lessons from the TPMT polymorphismClinical implications of aspirin resistanceAsthma pharmacogenetic study using finite mixture models to handle drug-response heterogeneityPharmacogenetics in inflammatory bowel diseaseIrinotecan pharmacogenomicsEffects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitroEffect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patientsA structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathwaysApplication of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effectMetabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?A Novel Drug-Mouse Phenotypic Similarity Method Detects Molecular Determinants of Drug EffectsProgress towards the integration of pharmacogenomics in practiceEvolution and medicine: the long reach of "Dr. Darwin"The resonance phenomenon in population persistence: can the same theory guide both national security policies and personalized medicine?Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing.The perceptions of pharmacists in Victoria, Australia on pharmacogenetics and its implications.
P2860
Q24273409-C1044BDD-3D9D-436A-B400-F0AB9D3A325FQ24317707-1263A85A-174A-41DE-BAF6-8C361B63CF13Q24607331-9874C51C-DB75-495C-9B5B-F6EC2E68D67EQ24615803-2529B4CD-0BA4-4CE2-AB7B-18DAC526857BQ24653629-03CBAF66-7AD6-4CE1-9302-E9AADA73D2E3Q24654656-0FA61862-27F2-41B5-B080-456109604105Q24815907-E41B2404-DE6E-45BC-96C7-B90602B77ACCQ26749954-A6B1549A-A728-48BB-9DA4-1844D7AE48FCQ26775808-2546A74E-89B8-4D01-8972-58610F87219FQ26777429-D97A4D15-04A7-4F71-B636-D83249C86FB5Q26824166-BD8DA354-F483-484C-ADBA-367113BFB075Q26827814-3E2E5850-DBB4-4CF4-B677-2584AFC6776DQ26830739-0BD92BDB-02C4-47AF-B0E8-A68FF839D7C2Q26859144-9D5D9249-C9EC-4E32-BDB2-E30ADF17CE97Q26861059-61033845-4C63-4301-BD60-0A880E7EF414Q26863704-374E7A90-9CDA-4AE9-AC42-6CE3C1BB799CQ26991936-E1FD896C-5BD6-469F-A10B-D164A0B34BDFQ27021716-36F60D34-BC00-4BD3-B4C3-CDF7C8AA8A96Q27026358-8B9D1300-EC60-428B-AD80-C35E1D7166C1Q27488354-7B78FBC2-975F-4071-8998-9393D9D7C4F2Q27497190-6DE70B15-40D5-4D82-845B-2AC586590EF0Q27692687-E56CC8DF-3841-407F-95A7-4F5A5BFFC912Q28082746-F81BE91F-837C-4EDE-BE01-91A7D85554B5Q28084874-147F63F1-4A8F-4033-8CE0-A08921C42C5CQ28212325-9FB87842-5421-485D-9628-C3A8978D98C2Q28221576-D8F51DE2-8D4A-4E1B-A0E1-F321D930F2F6Q28245359-9F9CD925-F10D-4B4C-97BD-FB3EACA289D2Q28246002-7ADA29BA-676D-4827-80EF-BF8565438166Q28287024-60E7EC11-C681-4E28-AF55-2BB8593FE1E3Q28295439-D11CB677-692B-40B9-B31C-FEFC6DB53485Q28382908-B44819C9-B655-4730-B53C-D63402947A32Q28475242-4B1B5FE6-1E0A-4495-8D09-F1022BCB4AA2Q28542007-734BFA30-ACA1-4D54-8A94-BB6EDAD2E784Q28546430-3F070F10-9C14-4A48-BD80-E3F46BB17D23Q28554371-590659F6-CBB9-4D60-9EC6-0BC1B2FA7D08Q28652270-412E5416-FCC8-4123-9FCD-A07B6B8875C8Q28762889-D6B0789D-9B69-4DBC-AC06-80233965E078Q30210378-F5B88044-B4BD-4E78-B718-538D856E4D7FQ30224766-82F48E0E-DA9F-437E-BE88-6C12D00FA44CQ30226502-BAEF3854-AEB8-4F99-AC1A-C65CD2670D8A
P2860
Pharmacogenomics--drug disposition, drug targets, and side effects.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pharmacogenomics--drug disposition, drug targets, and side effects.
@ast
Pharmacogenomics--drug disposition, drug targets, and side effects.
@en
Pharmacogenomics--drug disposition, drug targets, and side effects.
@nl
type
label
Pharmacogenomics--drug disposition, drug targets, and side effects.
@ast
Pharmacogenomics--drug disposition, drug targets, and side effects.
@en
Pharmacogenomics--drug disposition, drug targets, and side effects.
@nl
prefLabel
Pharmacogenomics--drug disposition, drug targets, and side effects.
@ast
Pharmacogenomics--drug disposition, drug targets, and side effects.
@en
Pharmacogenomics--drug disposition, drug targets, and side effects.
@nl
P356
P1476
Pharmacogenomics--drug disposition, drug targets, and side effects.
@en
P2093
Howard L McLeod
William E Evans
P304
P356
10.1056/NEJMRA020526
P407
P577
2003-02-01T00:00:00Z